Lachlan Gray

Dr. Lachlan Gray

ViiV Healthcare
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
FWFiona Wightman
Fiona Wightman
ASAjantha Solomon
Ajantha Solomon
GKGabriela Khoury
Gabriela Khoury
JGJustin A. Green
Justin A. Green
LGLachlan Gray
Lachlan Gray
Sharon LewinSharon Lewin
Sharon Lewin
Background. Naive T cell recovery is critical for successful immune reconstitution after antiretroviral therapy (ART), but the relative contribution

1 July 2005 in Virology
Verified
Journal Article
Closed access
LGLachlan Gray
Lachlan Gray
JSJasminka Sterjovski
Jasminka Sterjovski
MCMelissa Churchill
Melissa Churchill
PEPhilip Ellery
Philip Ellery
NNNajla Nasr
Najla Nasr
PGPaul R. Gorry
Paul R. Gorry

14 July 2011 in Blood
Verified
Journal Article
Open access
PDF file
AHAndrew N. Harman
Andrew N. Harman
JLJoey Lai
Joey Lai
Stuart TurvilleStuart Turville
Stuart Turville
SSShamith Samarajiwa
Shamith Samarajiwa
LGLachlan Gray
Lachlan Gray
Anthony L. CunninghamAnthony L. Cunningham
Anthony L. Cunningham
Many viruses have developed mechanisms to evade the IFN response. Here, HIV-1 was shown to induce a distinct subset of IFN-stimulated genes (ISGs) in monocyte-derived dendritic cells (DCs), without detectable type I or II IFN. These ISGs all contained an IFN regulatory factor 1 (IRF-1) binding site in their promoters, and their expression was shown to be driven by IRF-1, indicating this subset was induced directly by viral infection by IRF-1. IRF-1 and -7 protein expression was enriched in HIV p24 antigen-positive DCs. A HIV deletion mutant with the IRF-1 binding site deleted from the long terminal repeat showed reduced growth kinetics. Early and persistent induction of IRF-1 was coupled with sequential transient up-regulation of its 2 inhibitors, IRF-8, followed by IRF-2, suggesting a mechanism for IFN inhibition. HIV-1 mutants with Vpr deleted induced IFN, showing that Vpr is inhibitory. However, HIV IFN inhibition was mediated by failure of IRF-3 activation rather than by its degradation, as in T cells. In contrast, herpes simplex virus type 2 markedly induced IFNβ and a broader range of ISGs to higher levels, supporting the hypothesis that HIV-1 specifically manipulates the induction of IFN and ISGs to enhance its noncytopathic replication in DCs.

1 November 2014 in Current Opinion in HIV and AIDS
Verified
Journal Article
Closed access
LGLachlan Gray
Lachlan Gray
MRMichael Roche
Michael Roche
JFJacqueline Flynn
Jacqueline Flynn
SWSteve L. Wesselingh
Steve L. Wesselingh
PGPaul R. Gorry
Paul R. Gorry
MCMelissa J. Churchill
Melissa J. Churchill
Purpose of review To summarize the evidence in the literature that supports the central nervous system (CNS) as a viral reservoir for HIV-1 and to prioritize future research efforts. Recent findings HIV-1 DNA has been detected in brain tissue of patients with undetectable viral load or neurocognitive disorders, and is associated with long-lived cells such as astrocytes and microglia. In neurocognitively normal patients, HIV-1 can be found at high frequency in these cells (4% of astrocytes and 20% of macrophages). CNS cells have unique molecular mechanisms to suppress viral replication and induce latency, which include increased expression of dominant negative transcription factors and suppressive epigenetic factors. There is also evidence of continued inflammation in patients lacking a CNS viral load, suggesting the production and activity of viral neurotoxins (for example, Tat). Summary Together, these findings provide evidence that the CNS can potentially act as a viral reservoir of HIV-1. However, the majority of these studies were performed in historical cohorts (absence of combination antiretroviral therapy or presence of viral load), which do not reflect modern day patients (combination antiretroviral therapy-treated and undetectable viral load). Future studies will need to examine patient samples with these characteristics to conclusively determine whether the CNS represents a relevant and important viral reservoir.

12 December 2007 in Retrovirology
Verified
Journal Article
Open access
PDF file
JSJasminka Sterjovski
Jasminka Sterjovski
MCMelissa J Churchill
Melissa J Churchill
AEAnne Ellett
Anne Ellett
LGLachlan Gray
Lachlan Gray
MRMichael Roche
Michael Roche
PGPaul Gorry
Paul Gorry
CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively.

28 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LGLachlan Gray
Lachlan Gray
Stuart TurvilleStuart Turville
Stuart Turville
THTina L Hitchen
Tina L Hitchen
WCWan-Jung Cheng
Wan-Jung Cheng
AEAnne M Ellett
Anne M Ellett
MCMelissa J Churchill
Melissa J Churchill
Astrocytes are extensively infected with HIV-1 in vivo and play a significant role in the development of HIV-1-associated neurocognitive disorders. Despite their extensive infection, little is known about how astrocytes become infected, since they lack cell surface CD4 expression. In the present study, we investigated the fate of HIV-1 upon infection of astrocytes. Astrocytes were found to bind and harbor virus followed by biphasic decay, with HIV-1 detectable out to 72 hours. HIV-1 was observed to associate with CD81-lined vesicle structures. shRNA silencing of CD81 resulted in less cell-associated virus but no loss of co-localization between HIV-1 and CD81. Astrocytes supported trans-infection of HIV-1 to T-cells without de novo virus production, and the virus-containing compartment required 37°C to form, and was trypsin-resistant. The CD81 compartment observed herein, has been shown in other cell types to be a relatively protective compartment. Within astrocytes, this compartment may be actively involved in virus entry and/or spread. The ability of astrocytes to transfer virus, without de novo viral synthesis suggests they are capable of sequestering and protecting virus and thus, they could potentially facilitate viral dissemination in the CNS.